A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Council Meeting Considers Working Team to Explore Directions for Drug Distribution Improvement
March 21, 2012
-
ORGANIZATION Asia Partnership Conference Starts Talks for Early NDA Approval at Inauguration Meeting in Tokyo
March 19, 2012
-
BUSINESS Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
-
BUSINESS Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
-
ORGANIZATION JPMA Compiles Policies for Transparency in Patient Group Relationships, Disclosure for States of Donations
March 15, 2012
-
BUSINESS Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
-
BUSINESS Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
-
REGULATORY Convincing Data Needed to Perpetuate Premium for New Drug Development: Mr Yoshida of MED
March 13, 2012
-
BUSINESS Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic While Patent Dispute Continues
March 12, 2012
-
BUSINESS 20 Companies Review Risk Countermeasures After Earthquake, Novartis Looks into MR Standards of Behavior: Jiho Survey
March 9, 2012
-
BUSINESS Daiichi Sankyo to Integrate Global, Japan Business Management Functions into Four-Division Structure
March 8, 2012
-
ORGANIZATION Wholesale Industry FTC to “Watch Closely” How Drug Makers Respond to Tougher Rules on Business Entertaining
March 7, 2012
-
BUSINESS Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
-
REGULATORY 702 Products Including DPP-4 Inhibitors to Be Eligible for New Drug Premium in April
March 5, 2012
-
REGULATORY Private-Sector Members of Strategy Council Call for Early Establishment of Drug Discovery Support Organization
March 5, 2012
-
ORGANIZATION KSLION to Stimulate Innovation in Life Science in Japan: Prof. Y. Natsumeda
March 5, 2012
-
BUSINESS Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
-
BUSINESS DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
-
BUSINESS Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
-
REGULATORY MHLW Conducts Hearing on Distribution Improvement with Drug Manufacturers
February 28, 2012
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…